Compagnie Lombard Odier SCmA’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40.7K | Buy |
+450
| New | +$37.7K | ﹤0.01% | 381 |
|
|
2025
Q2 | – | Sell |
-1,200
| Closed | -$87K | – | 473 |
|
|
2025
Q1 | $87K | Buy |
+1,200
| New | +$85.9K | ﹤0.01% | 318 |
|
|
2024
Q1 | – | Sell |
-4,254
| Closed | -$324K | – | 529 |
|
|
2023
Q4 | $324K | Buy |
4,254
+504
| +13% | +$35.1K | 0.01% | 240 |
|
|
2023
Q3 | $260K | Hold |
3,750
| – | – | 0.01% | 238 |
|
|
2023
Q2 | $354K | Sell |
3,750
-2,200
| -37% | -$191K | 0.01% | 201 |
|
|
2023
Q1 | $492K | Sell |
5,950
-508
| -8% | -$39.9K | 0.01% | 199 |
|
|
2022
Q4 | $482K | Buy |
6,458
+323
| +5% | +$24.9K | 0.01% | 199 |
|
|
2022
Q3 | $508K | Buy |
6,135
+2,355
| +62% | +$227K | 0.01% | 214 |
|
|
2022
Q2 | $360K | Hold |
3,780
| – | – | 0.01% | 233 |
|
|
2022
Q1 | $445K | Hold |
3,780
| – | – | 0.01% | 224 |
|
|
2021
Q4 | $490K | Hold |
3,780
| – | – | 0.01% | 244 |
|
|
2021
Q3 | $428K | Hold |
3,780
| – | – | 0.01% | 259 |
|
|
2021
Q2 | $392K | Sell |
3,780
-3,300
| -47% | -$311K | 0.01% | 262 |
|
|
2021
Q1 | $592K | Sell |
7,080
-50,300
| -88% | -$4.25M | 0.01% | 256 |
|
|
2020
Q4 | $5.23M | Buy |
57,380
+20,000
| +54% | +$1.66M | 0.13% | 78 |
|
|
2020
Q3 | $2.98M | Buy |
37,380
+3,300
| +10% | +$257K | 0.09% | 90 |
|
|
2020
Q2 | $2.35M | Buy |
34,080
+8,910
| +35% | +$633K | 0.08% | 100 |
|
|
2020
Q1 | $1.58M | Sell |
25,170
-1,770
| -7% | -$128K | 0.07% | 104 |
|
|
2019
Q4 | $2.1M | Buy |
26,940
+6,390
| +31% | +$499K | 0.08% | 109 |
|
|
2019
Q3 | $1.51M | Buy |
20,550
+11,550
| +128% | +$811K | 0.06% | 111 |
|
|
2019
Q2 | $554K | Buy |
+9,000
| New | +$544K | 0.02% | 169 |
|
|
2019
Q1 | – | Sell |
-1,500
| Closed | -$77K | – | 583 |
|
|
2018
Q4 | $77K | Hold |
1,500
| – | – | ﹤0.01% | 349 |
|
|
2018
Q3 | $87K | Hold |
1,500
| – | – | ﹤0.01% | 366 |
|
|
2018
Q2 | $73K | Buy |
1,500
+750
| +100% | +$35K | ﹤0.01% | 392 |
|
|
2018
Q1 | $35K | Hold |
750
| – | – | ﹤0.01% | 484 |
|
|
2017
Q4 | $28K | Hold |
750
| – | – | ﹤0.01% | 531 |
|
|
2017
Q3 | $27K | Sell |
750
-3,600
| -83% | -$137K | ﹤0.01% | 583 |
|
|
2017
Q2 | $172K | Hold |
4,350
| – | – | 0.01% | 366 |
|
|
2017
Q1 | $137K | Sell |
4,350
-7,200
| -62% | -$225K | ﹤0.01% | 411 |
|
|
2016
Q4 | $360K | Sell |
11,550
-225
| -2% | -$7.29K | 0.01% | 372 |
|
|
2016
Q3 | $473K | Hold |
11,775
| – | – | 0.01% | 359 |
|
|
2016
Q2 | $391K | Hold |
11,775
| – | – | 0.01% | 379 |
|
|
2016
Q1 | $346K | Sell |
11,775
-7,125
| -38% | -$197K | 0.01% | 401 |
|
|
2015
Q4 | $498K | Buy |
18,900
+6,300
| +50% | +$164K | 0.02% | 318 |
|
|
2015
Q3 | $298K | Buy |
12,600
+6,000
| +91% | +$145K | 0.01% | 353 |
|
|
2015
Q2 | $156K | Sell |
6,600
-7,872
| -54% | -$178K | 0.01% | 480 |
|
|
2015
Q1 | $343K | Sell |
14,472
-7,884
| -35% | -$177K | 0.01% | 374 |
|
|
2014
Q4 | $475K | Sell |
22,356
-5,436
| -20% | -$109K | 0.02% | 275 |
|
|
2014
Q3 | $473K | Buy |
27,792
+14,094
| +103% | +$222K | 0.02% | 338 |
|
|
2014
Q2 | $196K | Hold |
13,698
| – | – | 0.01% | 527 |
|
|
2014
Q1 | $170K | Buy |
13,698
+9,300
| +211% | +$107K | 0.01% | 557 |
|
|
2013
Q4 | $48K | Buy |
+4,398
| New | +$49.6K | ﹤0.01% | 712 |
|
Other funds holding EW
Compagnie Lombard Odier SCmA's EW Position: Q2 2026 in Review
Compagnie Lombard Odier SCmA opened a new position in Edwards Lifesciences (EW) in Q2 2026: 450 shares worth $40.7K. The stake represents ﹤0.01% of the portfolio and ranks #381 among its holdings. This is a return to the name: Compagnie Lombard Odier SCmA previously reported a position in EW as recently as Q1 2025.
Compagnie Lombard Odier SCmA first reported a position in EW in Q4 2013 and has held it in 42 quarters since. The position peaked at $5.23M in Q4 2020. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Compagnie Lombard Odier SCmA held 450 shares of Edwards Lifesciences worth $40.7K as of Q2 2026.
- Edwards Lifesciences was a new Compagnie Lombard Odier SCmA position in Q2 2026.
- Edwards Lifesciences made up ﹤0.01% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #381 holding.
- Compagnie Lombard Odier SCmA first reported a position in Edwards Lifesciences in Q4 2013 and has held it in 42 quarters since.
- Compagnie Lombard Odier SCmA's Edwards Lifesciences position peaked at $5.23M in Q4 2020.
- 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.